Genitourinary Cancers | Specialty

ASCO 2019: Dr. Rajkumar Highlights Practice-Changing Multiple Myeloma Studies

June 2nd 2019

OncLive News Network On Location: In Chicago Tuesday, June 4

June 2nd 2019

OncLive News Network On Location: In Chicago Monday, June 3

June 2nd 2019

OncLive News Network On Location: In Chicago Sunday, June 2

June 2nd 2019

OncLive News Network On Location: In Chicago Saturday, June 1

June 2nd 2019

Dr. Balar on the Future of Immunotherapy in Bladder Cancer

May 29th 2019

Arjun V. Balar, MD, director, Genitourinary Medical Oncology Program, assistant professor, Department of Medicine, NYU Langone's Perlmutter Cancer Center, discusses the future of immunotherapy in bladder cancer.

Dr. McGregor on the Future of Cabozantinib in RCC

May 24th 2019

Bradley McGregor, MD, clinical director, Lank Center for Genitourinary Oncology, senior physician, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses the future of cabozantinib (Cabometyx) in renal cell carcinoma (RCC).

Dr. Rini on Managing the Toxicity of Pembrolizumab Plus Axitinib in mRCC

May 23rd 2019

Brian I. Rini, MD, professor of medicine, Cleveland Clinic, discusses managing the toxicity of pembrolizumab plus axitinib in patients with metastatic renal cell carcinoma.

Pembrolizumab Shows Promise for Unmet Need in NMIBC

May 22nd 2019

Arjun V. Balar, MD, highlights the KEYNOTE-057 study findings and provided insight into the role of immunotherapy in bladder cancer.

Dr. Meric-Bernstam Discusses Novel Combination in RCC

May 22nd 2019

Funda Meric-Bernstam, MD, chair, Department of Investigational Cancer Therapeutics, medical director, Institute for Personalized Cancer Therapy, professor of medicine, The University of Texas MD Anderson Cancer Center, discussed preliminary data with a novel combination in the treatment of patients with renal cell carcinoma.

Dr. Balar on Biomarkers of Immunotherapy Response in Bladder Cancer

May 22nd 2019

Arjun V. Balar, MD, assistant professor, Department of Medicine, director, Genitourinary Medical Oncology Program, NYU Langone's Perlmutter Cancer Center, discusses biomarkers of immunotherapy response in patients with bladder cancer.

Dr. Sznol on Factors to Consider When Combining VEGF TKIs/Immunotherapy in RCC

May 22nd 2019

Mario Sznol, MD, professor of medicine, co-director, Cancer Immunology Program, co-director, Yale SPORE in Skin Cancer, Yale Cancer Center, discusses factors to consider when combining VEGF TKIs with immunotherapy in renal cell carcinoma (RCC).

Targeted Therapies Offer Fresh Options in Urothelial Carcinoma

May 17th 2019

Oncologists looking for options beyond immuno-oncology for treating patients with metastatic urothelial carcinoma may soon have a range of targeted therapy choices.

Dr. Agarwal on Patient Selection in Frontline Advanced RCC

May 17th 2019

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine; and director, Genitourinary Oncology Program, Oncology Division, co-leader, Urologic Oncology Multidisciplinary Program, associate director of Clinical Trials, Huntsman Cancer Institute, discusses patient selection in the frontline treatment of patients with advanced renal cell carcinoma (RCC).

Dr. McGregor on the Utility of Axitinib/Avelumab in Advanced RCC

May 16th 2019

Bradley McGregor, MD, clinical director, Lank Center for Genitourinary Oncology, senior physician, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses the data with the combination of axitinib (Inlyta) and avelumab (Bavencio) in advanced renal cell carcinoma (RCC).

FDA Approves Avelumab/Axitinib for Frontline RCC

May 15th 2019

The FDA has approved the combination of avelumab and axitinib for the frontline treatment of patients with advanced renal cell carcinoma.

Dr. Quinn on the Biology of RCC

May 14th 2019

David I. Quinn, MD, MBBS, PhD, FRACP, FACP, associate professor of medicine, section head, Genitourinary Oncology, Division of Cancer Medicine and Blood Diseases, Department of Medicine, Keck School of Medicine, discusses the biology of renal cell carcinoma (RCC).

RCC Paradigm Continues to Rapidly Develop With TKI/IO Combos

May 13th 2019

Bradley McGregor, MD, speaks about the various data that have emerged in renal cell carcinoma with combinations of immunotherapy, TKIs, and how he chooses between the available treatments for his patients.

Dr. McGregor on Frontline Regimens in Advanced RCC

May 10th 2019

Bradley McGregor, MD, clinical director, Lank Center for Genitourinary Oncology, senior physician, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses frontline treatment regimens in advanced renal cell carcinoma (RCC).

Next Steps in Bladder Cancer Include Chemoimmunotherapy, Targeted Agents, and ADCs

May 9th 2019

Guru Sonpavde, MD, discusses the current use of immunotherapy and the numerous strategies in development in bladder cancer.